

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jun 2026

Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of chemoradiation Induced Oral Mucositis in head and neck malignancies

Protocol summary

Study aim

Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of chemoradiation Induced Oral Mucositis in head and neck malignancies

Design

This clinical trial was performed on 60 patients, divided into two groups of 30, including a control group and parallel groups. This study is blinded and simple randomization is used.

Settings and conduct

The field of work is clinical - internal. This study is performed in the Tohid Hospital in Sanandaj. The intervention group is given the solution containing Glycyrrhiza glabra and eucalyptus extract until the end of the course of radiotherapy. The control group is given the container containing the normal saline solution until the end of the course of radiotherapy,

Participants/Inclusion and exclusion criteria

Inclusion criteria: Head and neck carcinoma; Full awareness; Oral mucosal health Exclusion criteria: History of allergy to medicinal plants; High blood pressure; Diabetes; Autoimmune diseases; Cardiovascular disease; The presence of mucosal lesions in the mouth; Previous history of radiotherapy and chemotherapy; Chronic liver diseases; Non-use of drugs; alcohol; cigarettes

Intervention groups

Intervention group: The recipient of the solution containing Glycyrrhiza glabra and eucalyptus extract, Intervention until the end of the course of radiotherapy. Control group: The recipient of the container containing the normal saline solution, Intervention until the end of the course of radiotherapy

Main outcome variables

Incidence of severe mucositis (Grade 3 \leq); need for analgesics during treatment; time of onset of mucositis; duration of mucositis

General information

Reason for update

Given that the patient, evaluators, and statistical analyst were unaware of the group allocation, which is also mentioned in the blinding section, the present study was conducted in a triple-blind manner.

Acronym

IRCT registration information

IRCT registration number: **IRCT20190415043279N4**
Registration date: **2020-06-14, 1399/03/25**
Registration timing: **registered_while_recruiting**

Last update: **2025-10-06, 1404/07/14**

Update count: **1**

Registration date

2020-06-14, 1399/03/25

Registrant information

Name

Pezhman Sharifi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 87 3324 9435

Email address

p.sharifi@muk.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-06-22, 1398/04/01

Expected recruitment end date

2020-06-21, 1399/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of chemoradiation Induced Oral Mucositis in head and neck malignancies

Public title

Effect of local application of Glycyrrhiza glabra and eucalyptus extract for the prevention of Mucositis

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Head and neck carcinoma Full awareness Oral mucosal health

Exclusion criteria:

History of allergy to medicinal plants High blood pressure Diabetes Autoimmune diseases Cardiovascular disease Neutropenia The presence of mucosal lesions in the mouth Previous history of radiotherapy and chemotherapy Chronic liver diseases Active collagen vascular disease Non-use of drugs; alcohol; cigarettes

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

In this research, according to a randomized list, is assigned by a person outside the study according to the corresponding codes in the sealed envelopes, then assigned to any disease that is included in the study. Medications are identical in appearance, packaging, color, and so on.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Container solutions and placebo were identical with respect to appearance and only differed in coding of the capsules. The treatment code of the intervention supplements was blinded for subjects, investigators and staff involved in the conduct of the study.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Kurdistan University of Medical Sciences

Street address

Vice Chancellor for research of Kurdistan University of Medical Sciences, Pasdaran Blvd, Sanandaj, Iran

City

Sanandaj

Province

Kurdistan

Postal code

66177-13446

Approval date

2017-06-20, 1396/03/30

Ethics committee reference number

IR.MUK.REC.1396/75

Health conditions studied**1****Description of health condition studied**

Oral Mucositis

ICD-10 code

K12

ICD-10 code description

Stomatitis and related lesions

Primary outcomes**1****Description**

Incidence of severe mucositis (Grade 3≤)

Timepoint

The beginning of the intervention, every week continuously, the end of the intervention, one week after the end of the intervention

Method of measurement

Clinical examination by an oncologist and determination of mucositis grading using (NCI-CTCAE) version 4

Secondary outcomes**1****Description**

Need for painkillers during treatment

Timepoint

During the course of treatment

Method of measurement

Check list

2

Description

The incidence of any degree of mucositis

Timepoint

During the course of treatment

Method of measurement

Examination by an oncologist and registration in the checklist

3

Description

Time of onset of mucositis

Timepoint

When mucositis begins

Method of measurement

Examination by an oncologist and registration in the checklist

4

Description

Duration of mucositis

Timepoint

Time from onset to resolution of mucositis

Method of measurement

Examination by an oncologist and registration in the checklist

Intervention groups

1

Description

Intervention group: The recipient of the solution containing Glycyrrhiza glabra and eucalyptus extract, It is recommended to use 20 cc of it as a gargle for 30 seconds three times a day. Intervention until the end of the course of radiochemotherapy, the solution is prepared by a phytochemical specialist in a specialized laboratory.

Category

Prevention

2

Description

Control group: The recipient of the container containing the normal saline solution, It is recommended to use 20 cc as a gargle for 30 seconds. Intervention until the end of the course of radiochemotherapy, the solution is prepared by a phytochemical specialist in a specialized laboratory.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Tohid Hospital

Full name of responsible person

Bayazid Ghaderi

Street address

Tohid Hospital, Geriashan Ave

City

Sanandaj

Province

Kurdistan

Postal code

6616812131

Phone

+98 87 3366 4645

Email

bayazid.g@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Afshin Maleki

Street address

Vice Chancellor for research of Kurdistan University of Medical Sciences, Pasharan Blvd, Sanandaj, Iran.

City

Sanandaj

Province

Kurdistan

Postal code

6617713466

Phone

+98 87 3366 4645

Email

maleki43@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Sanandaj University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Bayazid Ghaderi

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Blood and oncology

Street address

Kurdistan University of Medical Sciences, Pasdaran Blvd, Sanandaj, Iran

City

Sanandaj

Province

Kurdistan

Postal code

6617713466

Phone

+98 87 3366 4645

Email

bayazid.g@yahoo.com

+98 87 3366 4645

Email

bayazid.g@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

bayazid Ghaderi

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Blood and oncology

Street address

Kurdistan University of Medical Sciences, Pasdaran Blvd, Sanandaj, Iran

City

Sanandaj

Province

Kurdistan

Postal code

6617713466

Phone

+98 87 3366 4645

Email

bayazid.g@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Sanandaj University of Medical Sciences

Full name of responsible person

Bayazid Ghaderi

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Blood and oncology

Street address

Kurdistan University of Medical Sciences, Pasdaran Blvd, Sanandaj, Iran

City

Sanandaj

Province

Kurdistan

Postal code

6617713466

Phone

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Not applicable

Analytic Code

Not applicable

Data Dictionary

Not applicable